David A. Sinclair, PhD, AO is a professor in the Department of Genetics at Harvard Medical School, president of the Academy for Health and Lifespan Research, and best known for his work on understanding why we age and how to slow its effects. His lab is working on epigenetic changes as a driver of aging and the use of reprogramming factors to reset the age of cells and tissues. He has published over 200 scientific papers, is a co-inventor on over 50 patents, co-founded biotech and consumer companies, four of which have gone public, and is the author of the New York Times bestselling book Lifespan: Why We Age and Why We Don’t Have To. He serves as co-chief editor of the scientific journal Aging and has received more than 35 honors including the Australian Medical Research Medal, the NIH Director’s Pioneer award, and has been on TIME magazine’s lists of the “100 most influential people in the world” and the “Top 50 people in Healthcare”. He is an Officer of the Order of Australia (AO) and serves on the non-profit board of the American Federation for Aging Research.

Bracken Darrell is the president & chief executive officer of VF Corporation, one of the world’s largest apparel, footwear, and accessories companies. For the 10 years prior, Bracken served as president & chief executive officer at Logitech. His career spans more than 30 years and includes experience in business and brand management in successful global consumer companies including Whirlpool, Procter & Gamble, and General Electric. His broad executive management experience covers manufacturing, supply chain, product innovation, consumer services, and marketing—targeting customers in mature and emerging markets. Bracken began his career with Arthur Anderson and then PepsiCo. Bracken holds an MBA from Harvard Business School and a BA in English from Hendrix College in Arkansas.

Stuart Gibson is the executive director, group co-founder & co-CEO of ESR, APAC’s largest real asset manager powered by the New Economy and the third largest listed real estate investment manager globally. He was also a co-founder and CEO of the Redwood group. He has over 27 years of real estate development and investment experience in Asia, which includes 15 years in the Japanese industrial real estate sector. Stuart was formerly the country head of Prologis Japan, and former co-founder and co-CEO of AMB BlackPine, which was subsequently incorporated into Prologis. He was also the chairman of AMB Property Corporation Japan Advisory Committee.

Jerry McLaughlin is chief executive officer and board member of Life Biosciences, Inc. He has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development, and global commercialization of more than a dozen FDA-approved drugs with multiple successful exits. Most recently, Jerry was president & CEO for Neos Therapeutics, Inc., a commercial stage pharmaceutical company. Before that, he served as president & CEO of AgeneBio, Inc., a clinical-stage private biopharma company developing therapies for neurological and psychiatric diseases. Earlier, he held the role of senior vice president & chief commercial officer at NuPathe Inc., acquired by Teva Pharmaceuticals in 2014. Jerry began his career at Merck and was extensively involved in multiple blockbuster product launches. He holds a BA in economics from Dickinson College and an MBA from the Villanova School of Business.

Ilan Stern is a board director of Flow, a co-founder of FlowCarbon, and chief investment officer of 166 2nd Asset Management, a single family office. Before 166 2nd, Ilan was a general partner and managing director at General Catalyst, a top tier venture firm. Prior to General Catalyst, Ilan was a portfolio manager at Soros Fund Management where he led several portfolios and teams and managed several billions in capital. Ilan started his career at Bear Sterns on Non-Agency Mortgage-Backed Securities and served as a vice president of ABS Trading at Merrill Lynch & Co.